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All double-stranded DNA bacteriophages encode a specialized set of proteins that allow progeny 
phages to escape the current host cell at the end of the lytic cycle. At a minimum, this lytic 
cassette consists of a holin and an endolysin to destabilize the host’s plasma membrane and 
peptidoglycan layer, respectively. This two-enzyme system is sufficient to break open most 
Gram-positive hosts, but the phages of bacteria with more complex cell walls often encode 
additional lysis proteins. For example, the mycobacteria have thick, waxy, mycolic acid-rich cell 
walls that aid in their antibiotic resistance. Therefore, their phages—the mycobacteriophages—
also encode a lysterase (LysB), in order to efficiently overcome this barrier. In vitro, these serine 
esterase proteins have been shown to hydrolyze mycolic acids from whole mycobacterial cells 
and purified cell wall components. Our data also show that exogenous addition of purified 
lysterases has antimicrobial activity against several species within the Order Actinomycetales, 
including bacteria associated with disease and—surprisingly—bacteria that do not contain 
mycolic acids, such as Cutibacterium acnes. C. acnes is the implicated causative bacteria in the 
skin disease acne vulgaris and is an opportunistic pathogen in eye, blood, and medical device 
infections. While the identity of the LysB target on C. acnes is still unknown, we have tested 
LysB activity against multiple clinically relevant strains of C. acnes and have shown that LysB 
treatment releases an unidentified lipid from whole C. acnes cells. 
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1.0  PHAGE-MEDIATED LYSIS OF BACTERIAL CELLS 
The general bacteriophage—a virus that infects bacteria—must be able to accomplish a 
minimum of four tasks in order to complete its life cycle (Figure 1): 1) the phage must be able to 
find a host cell and inject its genome; 2) the phage genome must be replicated; 3) progeny 
phages must be assembled; and 4) progeny phages must be able to escape the host cell so that the 
life cycle can repeat anew1–3. Therefore, phage must be able to exploit host machinery and/or 
encode their own genes to complete these tasks. For the purposes of this Masters Thesis, I will 
focus exclusively on the final part of the phage life cycle: escape from the current host cell. All 
tailed double-stranded (ds) DNA phages encode a specialized set of genes to accomplish this 
task; these genes are almost always located adjacent to one another and are, therefore, referred to 
as the lytic cassette4–6. These proteins work together in different areas of the bacterial cell wall to 
efficiently lyse the host cell. 
 There are three main strategies for phage escape from the current host cell. First are the 
filamentous bacteriophages, which extrude from the host7, are not lytic, and will not be further 
discussed in this document. Other bacteriophages either actively degrade cell wall components—
usually with muralytic enzymes targeting the peptidoglycan layer—or encode a single non-
muralytic enzyme—such as an inhibitor of murine synthesis—to achieve lysis5,7,8. These two 
strategies are employed by dsDNA phages of a range of hosts and single-stranded (ss) DNA or 
RNA phages of Gram-negative hosts, respectively5,7; though whether these strategies result in 
complete destruction of the host bacterium or simply cellular emptying depends on the phage in 
question5. Generally, the phage-encoded muralytic enzyme involved in lysis is called an 
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endolysin and lacks a signal sequence, a length of amino acids which enables the proteins to be 
translocated through the plasma membrane. Therefore, bacteriophages that utilize endolysins 
require another protein, a holin, to help them reach the peptidoglycan layer and correctly time 
lysis5,6. In the Escherichia coli phage λ—possibly the most-well studied bacteriophage—the 
holin and endolysin are encoded by the genes S and R, respectively. 
 
Figure 1. Temperate bacteriophage life cycle  
After adsorbing to a bacterium, a bacteriophage (orange) injects its genome (black) into the host. If the phage is 
temperate, it makes a decision to grow either lytically or lysogenically, in which the phage genome is usually 
integrated into the genome of the host bacterium (light blue) and as the host replicates, so does the phage. In some 
cases, the phage genome is not integrated and instead is maintained as a plasmid as the host replicates. Lytic phages 
and temperate phages that have flipped the genetic switch toward lytic growth, then hijack host transcription and 
translation machinery to create progeny phages. Finally, progeny phages must escape the current host cell so they 
may find new hosts. The phage life cycle is numbered to reflect the four necessary tasks a phage must complete, as 
detailed in the text. 
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1.1 TWO-ENZYME PHAGE-MEDIATED LYSIS 
1.1.1 Holins 
While most phages harbor a bioinformatically predicted holin gene, our knowledge about holin 
structure and function comes almost exclusively from coliphages like λ. Holins are a diverse 
group of functional homologs that share little sequence similarity and are the first protein 
involved in bacterial cell lysis. While many details of holin action and timing are still unclear, 
holins are transmembrane proteins that accumulate in the bacterial plasma membrane and control 
the timing of lysis7. When a sufficient number of canonical holin proteins—exemplified by the 
protein product of λ gene S–have accumulated, they oligomerize and create holes in the plasma 
membrane5,8,9. This action disrupts membrane potential, compromises the structural integrity of 
the membrane, and creates lesions through which subsequent lysis proteins can access their 
targets in more distal portions of the cell wall5. Translation of S can initiate at the first or third 
codon, making S a dual-start gene7. If translation starts at the 3rd codon, the resulting 105-amino 
acid protein is the lethal holin. Translation from the first codon produces a 107-amino acid anti-
holin, which opposes holin activity and helps regulate the timing of lysis5,7. Many holin systems 
include an anti-holin, though they are not always encoded by the same gene10.  
1.1.2 Endolysins 
The endolysins are a family of modular proteins that participate in host cell lysis through the 
degradation of bonds in the peptidoglycan layer. Unless the bacteria are grown in iso-osmotic 
media, high internal osmotic pressure will rapidly empty the cell contents into the environment 
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once the peptidoglycan layer has been compromised7. At a minimum, an endolysin has two 
domains, a C-terminal cell wall binding domain (CBD) that localizes the enzyme to its specific 
target and an N-terminal catalytic domain to hydrolyze that bond11–14. Endolysins can have 
different types of catalytic activity in the bacterial cell wall; lysozymes target glucosamine or 
muramine moieties, amidases target amide bonds linking the glycan strand and peptide moieties, 
and endopeptidase domains target peptide cross-bridges14–16.  
1.1.3 Pinholins and Signal-Anchor-Release Endolysins 
A notable variation to the holin-endolysin system described above is that of pinholins and signal-
anchor-release (SAR) endolysins. In this case, pinholin and SAR endolysin proteins are both 
incorporated into the plasma membrane5,7. Unlike canonical holins, pinholins do not cause large 
lesions in the plasma membrane, although they still disrupt membrane potential and structural 
integrity17,18. SAR endolysins have a hydrophobic N-terminal sequence that keeps the CBD and 
catalytic domains tethered inside the periplasmic space away from their targets19,20. When 
membrane potential collapses, SAR endolysins are released from the plasma membrane and can 
reach their targets in the peptidoglycan layer.  
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1.2 ADDITIONAL LYSIS ENZYMES 
These two enzyme holin-endolysin systems are sufficient to lyse most Gram-positive bacterial 
hosts. However, for the phages of hosts with more complicated cell walls, additional lytic 
enzymes are sometimes necessary for efficient lysis. 
1.2.1 Canonical cell walls 
The cell walls of canonical Gram-positive and Gram-negative bacteria are structured 
dramatically differently, and they impose different challenges for phage lysis. The mycobacterial 
cell wall poses yet another kind of challenge for phage lysis. In order to highlight why some 
bacteriophages might need additional lytic enzymes and how and where these proteins 
participate in lysis, we shall first introduce the basic components of these cell wall types.  
While the exact composition of any bacterial cell wall is unknown, certain common 
features and the properties of those features have allowed essentially all bacteria to be sorted into 
two major groups. Gram-positive and Gram-negative bacteria are first differentiated by their 
reaction to Gram stain. Crystal violet is used to stain peptidoglycan purple. The thick 
peptidoglycan layer of Gram-positive bacteria retains the dye even after the alcohol is added, 
while the comparatively thinner peptidoglycan layer of Gram-negative bacteria does not. When 
the counterstain is applied, only the Gram-negative bacteria will appear pink. Moving from the 
cytoplasm outward, the Gram-positive cell wall (Figure 2A, adapted from Payne21) is 
characterized by a plasma membrane, periplasmic space, and thick peptidoglycan layer22. 
Furthermore, Gram-positive bacteria can have a myriad of lipids and polysaccharides attached to 
 6 
their cell walls23, some—like teichoic acid—have been characterized, but most remain 
unidentified. 
 
 
 
 
 
1.2.2 Gram-negative bacteria and spanins  
The cell wall of Gram-negative species (Figure 2B, adapted from Payne21) is generally 
comprised of a plasma membrane, periplasmic space, a comparatively thinner peptidoglycan 
layer, and an outer membrane with exterior complex carbohydrates24. While the Gram-positive 
Figure 2. Models of Gram-positive and Gram-negative cell walls and their phages’ lysis proteins. 
The Gram-positive cell wall consists of a plasma membrane, periplasmic space, and thick peptidoglycan layer with 
attached teichoic acids. The Gram-negative cell wall also has a plasma membrane and periplasm, but it contains a 
thinner peptidoglycan layer, an outer membrane, and finally exterior complex carbohydrates. The phages of both 
types of bacteria encode a holin and endolysin to collapse membrane potential and degrade the peptidoglycan 
layer, respectively. Some phages of Gram-negative bacteria also encode spanins, which fuse the inner and outer 
membranes for concurrent destabilization. Bacterial cell wall parts are labeled in white boxes; phage proteins are 
labeled in colored ovals. 
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cell wall is comprised of 30-70% peptidoglycans22, peptidoglycan makes up less than 10% of the 
Gram-negative cell wall25. Gram-negative cell walls are also lipid-rich, but, again, little is known 
about the specific lipids.  
In addition to a holin and endolysin, some phages of Gram-negative bacteria, such as 
phage λ, produce spanins—encoded by genes Rz and Rz1—which fuse the inner and outer 
membranes of the Escherichia coli host cell, so that both membranes are compromised 
concurrently7,26,27. Under the right conditions, defective Rz and/or Rz1 will terminate lysis in a 
spherical cell shape28, presumably because the outer membrane is still intact. However, under 
standard laboratory conditions, spanins are not essential for lysis7,28,29.  
1.2.3 Mycobacterial cell wall and lysterases 
The mycobacteria—exemplified by Mycobacterium tuberculosis, the causative pathogen of the 
lung disease tuberculosis—have historically been categorized as Gram-positive bacteria due to 
their thick peptidoglycan layer and lack of true outer membrane30. However, these acid-fast 
bacteria are more accurately considered Gram-variable, as they lack a true outer membrane but 
often do not stain Gram-positive because of their waxy, lipid-rich cell walls. Along with the 
plasma membrane, the defining characteristics of their cell walls (Figure 3, adapted from 
Payne21) include the mycolylarabinogalactan-peptidoglycan (mAGP) complex, which consists of 
a peptidoglycan layer covalently attached to an arabinogalactan layer. The arabinogalactan is in 
turn covalently linked to the mycolic acids that lend their name to the mycobacteria30–33. Finally, 
interdigitated with the mycolic acids is an asymmetric bilayer comprised of a variety of free 
lipids and glycolipids, such as trehalose dimycolate (TDM)33. This outer most region of the cell 
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wall is sometimes referred to as the “mycobacterial outer membrane” and poses another barrier 
to lysis. 
 
 
 
 
 
To overcome the barrier of the mycobacterial outer membrane, in addition to a holin and 
endolysin, mycobacteriophages encode a lysterase (LysB)6,34,35. Lysterases have formerly been 
categorized as a type of endolysin—called Lysin B after the endolysin’s Lysin A (LysA) in the 
mycobacteriophage genome annotation convention34. However, we suggest the new 
Figure 3. Model of the mycobacterial cell wall and mycobacteriophage lysis proteins. 
The mycobacterial cell wall has a plasma membrane, mycolylarabinogalactan-peptidoglycan (mAGP) complex, and 
an asymmetric bilayer of free lipids and glycolipids such as trehalose dimycolate (TDM). While the 
mycobacteriophages encode holins and endolysins like the phages of Gram-positive and –negative bacteria, they 
also encode a lysterase. The lysterase hydrolyzes mycolic acids from the mycobacterial outer membrane to help 
efficiently lyse the host cell. Bacterial cell wall parts are labeled in white boxes; phage proteins are labeled in 
colored ovals. 
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classification of lysterase, as endolysins and lysterases are starkly different in terms of sequence 
and target molecule. While endolysins target bonds in the peptidoglycan layer, lysterases 
specifically hydrolyze mycolic acids from their ester-linked substrates in the mycobacterial cell 
wall. Details of lysterase activity will be discussed further in Chapter 3. Additionally, while all 
fully sequenced mycobacteriophage genomes on phagesdb.org36 have annotated LysA genes, 
only 89% of these genomes contain bioinformatically-identified LysB genes. Payne et al 200935 
used Bacteriophage Recombineering of Electroporated DNA37 (BRED) to delete the lysB gene in 
mycobacteriophage Giles. The ΔlysB mutant was recovered, but resulted in smaller plaques and 
had a defect in lysis when grown in liquid culture35. This suggests that while lysB may not be 
essential, it is necessary for the efficient lysis of mycobacterial hosts, as wildtype Giles phages 
would have timing and burst size advantages over ΔlysB mutants. 
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2.0  PHAGE-ENCODED ENZYMES AS ANTIMICROBIAL AGENTS 
2.1 INTRODUCTION 
While understanding how mycobacteriophage achieve lysis of their hosts is inherently interesting 
to phage biologists, there is obvious translational appeal to studying molecules involved in 
killing bacteria. Traditional antibiotics have been isolated from fungal and bacterial sources, but 
with resistance to antibiotics constantly increasing, it is necessary to continue searching for new 
antimicrobial therapies. Bacteriophage proteins are unsurprisingly an important potential source.  
2.2 ENDOLYSINS AS ANTIMICROBIALS 
To date, the endolysins are the most studied phage-encoded antimicrobial protein. At the 1st 
International Symposium on Antimicrobial Hydrolytic Enzymes in November 2016, twenty-two 
of the thirty speakers presented specifically on endolysins. Because of their inherent ability to 
lyse bacterial cells during the phage life cycle, it was hypothesized and found that endolysins 
from phages of Gram-positive bacterial hosts can effectively lyse bacterial suspensions when 
added exogenously12–14,38–40. Furthermore, it has been found that the CBD of various endolysins 
confer very specific antibacterial activity; that is, in most cases, an endolysin only has 
antibacterial activity against the natural host species of the phage that encodes the protein14. This 
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is, of course, not without exception, though most endolysins that can kill other bacteria can only 
kill those very closely related to their original host taxa, often limited to within the same genus13.  
This specificity makes endolysins promising narrow-spectrum antimicrobials, able to 
discriminate specific pathogens from other microbial flora. For example, in the dairy industry, 
endolysin are already being used to selectively kill bacteria that contaminate the essential 
lactobacilli cultures41,42. Additionally, the high specificity of endolysin CBDs is being explored 
as a diagnostic tool. For example, fluorescent proteins fused to CBDs from Listeria phages can 
selectively label Listeria species in mixed cultures; some CBDs can even differentiate between 
Listeria species16,43,44. Another advantage of endolysins is that, to date, susceptible bacteria have 
never been seen to acquire resistance14. Two companies, Contrafect and Elanco, have optioned 
patents to develop therapeutic endolysins for human and animal use, respectively. Contrafect has 
concluded Phase I clinical trials of their CF-301 endolysin45. Meanwhile a number of research 
and commercial laboratories continue to investigate their antimicrobial and diagnostic use on a 
wide range of bacteria12,13,16,38–41,43,44,46–49. 
2.3 TAIL-ASSOCIATED HYDROLASES 
Recently, the ability of phage tail-associated hydrolase proteins is being investigated for 
antimicrobial potential50. In vivo, these proteins are located on the tip of a bacteriophage tail, are 
often structurally essential, and aid in the phage’s ability to overcome the barrier of the cell wall 
during the initial stage of infection51–53. Once the cell wall has been compromised, the 
bacteriophage genome can make its way into the host cell. During instances of high multiplicity 
of infection (MOI), these tail-associated hydrolases aid in the process of lysis-from-without54, the 
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phenomenon of bacterial lysis induced by phage adsorption at high MOI and occurs without 
progeny phage production54,55. Despite their peptidoglycan-degrading activity, these enzymes are 
distinct from endolysins and have at least been identified in E. coli56–59, Salmonella59, 
Lactobacillus lacti60, Bacillus61, and Staphylococcus aureus62–64 bacteriophages. One such 
protein—called a tail-associated muralytic enzyme (TAME)—from S. aureus phage K, has been 
combined with the CBD of lysostaphin and was shown to be effective in killing staphylococci in 
a rat nasal colonization model64. 
2.4 TOXINS 
The term “toxin,” in this case, is used to differentiate any bacteriophage-encoded protein with 
antimicrobial activity that is not used in initial infection or in final lysis of the host bacterium. 
Many genes in bacteriophage genomes have no predicted known function, and investigating 
these can lead to the discovery of new antimicrobial gene products. PK34, a synthetic peptide 
created from gene 63 from mycobacteriophage D29, has been shown to bind trehalose 
dimycolate in the mycobacterial outer membrane, resulting in M. tuberculosis killing and 
inflammation inhibition in a mouse model65,66. The Hatfull laboratory has also been investigating 
possible mycobacteriophage-derived toxins. For example, the product of mycobacteriophage 
Fruitloop gene 52 is toxic when overexpressed in M. smegmatis and interacts with Wag31, an 
essential gene involved in cell shape and cell wall integrity (Ching-Chung Ko, unpublished data). 
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3.0  LYSTERASE ANTIMICROBIAL ACTIVITY 
Investigating phage-encoded proteins with potential antimicrobial activity has clear biomedical 
relevance. The respiratory disease tuberculosis is the world’s most deadly disease caused by a 
single pathogen, killing nearly two million people annually and harbored in an estimated two 
billion worldwide67. The causative pathogen, M. tuberculosis (Mtb), is notoriously difficult to 
diagnose and treat, as it has the thick, waxy mycolic acid-rich cell wall characteristic of its 
genus, is a slow growing, intracellular pathogen, and is often encased within granulomas in the 
lung. Diagnosis most commonly relies on microscopic identification and culturing the bacterium, 
which requires acquiring sufficiently high numbers of the bacilli from patient sputum and several 
weeks of incubation time, respectively68. More recently, a polymerase chain reaction (PCR) 
diagnosis method has been developed, which is much faster and requires less bacteria69. 
Unfortunately, this method is limited by efficiency of DNA extraction and currently requires a 
costly combination of harsh chemicals and mechanical sonication to break apart M. tuberculosis 
cells to reach their DNA70. Further, the front lines of Mtb infection usually lack access to such 
expensive diagnostic tools67.  
Treatment is equally difficult and costly, and treatment is often started before a positive 
diagnosis if the patient has come in contact with a known infected individual71. A treatment 
regime is often several months long, involves multiple antibiotics, and can change as various 
information is obtained67,71–73. For example, a patient may be started on a drug cocktail of 
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isoniazid, rifampin, pyrazinamide, and either streptomycin or ethambutol. If the Mtb strain in 
question turns out to be antibiotic susceptible, streptomycin and ethambutol treatment can be 
withdrawn, but antibiotic resistance rates are always increasing, including multidrug resistant 
(MDR) and extensively drug resistant (XDR) strains67,71. Additionally, these drugs themselves 
have a number of harmful side effects. Taken together, it is clear that any enzyme with the ability 
to break down the cell wall and potentially kill mycobacteria is worth investigating. 
3.1 LYSTERASE CATALYTIC ACTIVITY 
The lysterases were originally considered a second type of endolysin, but early studies showed 
that the two types of proteins have very different activity. The LysB from mycobacteriophage 
Ms6 was found to have lipolytic activity, being able to hydrolyze lipase and esterase substrates; 
the Ms6 LysB did not have hemolytic or proteolytic activity34. Lysterases from 
mycobacteriophages Ms634,74, D2935, and Bxz274 are able to hydrolyze p-nitrophenyl from 
carbon chains of varying lengths, representing canonical esterase and lipase activity, though the 
specific activity (in units per milligram) differed by LysB in these experiments. Treatment with 
D29 LysB releases free mycolic acids from purified mycobacterial cell wall components such as 
the mycolylarabinogalactan-peptidoglycan (mAGP) complex and trehalose dimycolate75. 
Additionally, when we treated whole M. smegmatis cells with Bxb1 or D29 LysB, we also saw 
an increase in free mycolic acids (Figure 4A) and a decrease in trehalose dimycolate and 
corresponding increase in trehalose monomycolate (Figure 4B). Some of the cells were boiled 
before LysB treatment to control for any stress response the cells might mount (Figure 4 “heat 
killed cells” vs other lanes). Since the beginning of my investigation into lysterase activity, 
 15 
exogenous Ms674, Bxz274, and BTCU-176 LysB proteins have demonstrated some antimicrobial 
activity against Mycobacterium smegmatis. 
 
 
 
3 
 
In the pages that follow, we tested LysB proteins from two mycobacteriophages: D29 and 
Bxb1. These proteins share only 21% sequence identity and were selected for multiple reasons. 
First, the D29-encoded LysB is one of the best-studied lysterases thus far and is the only LysB 
with a solved crystal structure (PDB: 3HC7)35 (Figure 5A, grey). Additionally, these two LysBs 
were easily cloned and overexpressed and represent the two structural classes of lysterase 
Figure 4.  LysB treatment releases lipids from whole M. smegmatis cells. 
Treatment with either LysB leads to an increase in free mycolic acids (FM), which can be seen as a darkening of the 
band indicated by the FM arrow in the Bxb1 and D29 lanes in comparison to the buffer control lane (A). Similarly, 
LysB treatment affected cell wall glycolipids, trehalose dimycolate (TDM) and trehalose monomycolate (TMM). 
Treatment resulted in a decrease in TDM and an increase in TMM, as indicated by the lightening of the TDM band 
and a darkening of the TMM-denoted band (B) in comparison to the control condition. Half of the cells were heat 
killed (where indicated) prior to treatment in order to control for any stress response by the cells. Optimized running 
conditions77 for visualizing (A) FM and (B) the difference between TDM and TMM as described in the methods 
section. 
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predicted from sequence data: one defined by the D29 LysB protein and comprised of a single 
domain, whereas the Bxb1 LysB (Figure 5A, green) has a predicted additional N-terminal 
domain of unknown function (Figure 5B, green). No studies have investigated the role of the N-
terminal domain, but it has HHpred78,79 predicted structural similarity to the CBD of a 
Pseudomonas phiKZ bacteriophage (PDB:3BKH)80 (Figure 5B, orange), although the two 
domains share only 19% sequence identity. 
 
 
Figure 5. Lysterase structure. 
A ribbon diagram alignment of the solved crystal structure of the mycobacteriophage D29 (gray) and a 
MODELLER79,81-predicted Bxb1 (green) lysterase proteins (A). The N-terminal domain of the Bxb1 LysB (green) 
and the cell wall binding domain of the Pseudomonas phage phiKZ endolysin (orange) (B). 
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3.2 RESULTS 
We first set out to determine whether lysterases had any effect on bacteria when added 
exogenously. In vivo, lysterases are translated within the cell; therefore, they would first 
encounter the mycobacterial outer membrane at the mAGP complex where ester-linked mycolic 
acids are abundant. However, unlike in studies with endolysins from Gram-positive 
bacteriophage, whose targets in the peptidoglycan layer should be accessible to exogenously 
added enzymes, it was unclear whether lysterases would be able to find their targets from outside 
of the cell. 
3.2.1 Lysterase activity against mycobacteria 
M. smegmatis mc2155 was grown to log-phase and suspended in phosphate buffered saline plus 
Tween (PBST). The cells were then treated with 2 µM of D29 or Bxb1 LysB or an equivalent 
volume of protein storage buffer as a negative control and incubated at 37ºC with agitation. At 
set timepoints, an aliquot of cells was removed, serially diluted, and spotted onto appropriate 
growth media agar plates. After several days, killing activity was assessed by comparing 
surviving colony forming units (cfu) from each LysB treatment to those from the negative 
control-treated cells. Surprisingly, not only were the LysB proteins apparently able to find their 
target when added exogenously, but their activity led to dramatic reduction of M. smegmatis 
mc2155 survival within five minutes of incubation (Figure 6A). These experiments were also 
performed using stationary-phase cells, and similar results were observed. 
To be sure this antimicrobial activity was due to the catalytic activity of the protein, as 
opposed to any artifacts of the experimental methods, site-directed mutagenesis was used to 
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change the catalytic serine (S158) of the Bxb1 LysB to an alanine. When the killing assay was 
repeated with this mutant, the catalytically inactive Bxb1 LysB had no effect on M. smegmatis 
survival (Figure 6B). Payne et al showed that mutating the catalytic serine (S82) to an alanine in 
the D29 LysB also abolished catalytic activity35.  
 
 
 
Figure 6. LysB treatment has an antimicrobial effect on M. smegmatis 
Cells were incubated with LysB or buffer control until the indicated timepoint, at which an aliquot was removed, 
serially diluted, and spotted onto 7H10 agar plates. After 3-4 days, cell growth was compared across conditions. 
Incubating M. smegmatis cell suspensions with either D29 or Bxb1 LysB results in a dramatic decrease in survival 
after as little as five minutes (A). This killing activity is abolished when the catalytic serine is mutated to an alanine 
(B). 
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M. smegmatis is the mycobacteria laboratory workhorse, as they are much easier to grow 
than M. tuberculosis. For example, M. smegmatis takes only a few days to produce single 
colonies, whereas M. tuberculosis requires three weeks. However, it cannot be assumed that M. 
smegmatis is a perfect surrogate for M. tuberculosis. Therefore, we tested LysB activity against 
M. tuberculosis mc27000, an avirulent mutant strain of M. tuberculosis82. Similar reduction in 
surviving cells was observed when M. tuberculosis mc27000 was treated with the LysB proteins 
(Figure 7). These results are in agreement with recent publications, in which LysBs—from other 
mycobacteriophages—were tested against mycobacteria74,76. 
    
 
 
 
Figure 7. M. tuberculosis is susceptible to LysB antimicrobial activity 
Cells were incubated with LysB or buffer control until the indicated timepoints, at which aliquots were removed, 
serially diluted, and spotted onto 7H11 agar plates. After two weeks, cell growth was compared across conditions. 
Both D29 and Bxb1 lysterases were also able to reduce the amount of M. tuberculosis survival. Cells needed to be 
incubated for at least ten minutes to see this effect. 
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3.2.2 Development of lysterase resistance 
The development of antibiotic resistance is a major concern when treating any bacterial infection 
and some experts believe we are rapidly progressing toward a post-antibiotic era83,84. 
Fortunately, bacteria susceptible to endolysin treatment have never demonstrated the ability to 
develop resistance to the enzyme14. It is hypothesized that, because of the millennia of 
coevolution between the phages and their hosts, phage lysis enzymes have evolved to target 
immutable bacterial cell wall components14. Therefore, we were also interested in whether the 
mycobacteria could develop resistance to lysterase activity. 
M. smegmatis cells that had survived the Bxb1 LysB or control treatment in an initial 
killing assay were used to seed new cultures. These cultures were then used in another round of 
killing assay. The original M. smegmatis culture was also passaged and used as a negative 
control. Therefore, for each generation of killing assay after the initial assay, three sets of M. 
smegmatis cells were used: naïve, buffer-treated, and Bxb1 LysB-treated. This method was then 
repeated for a total of three generations of killing assay. Survival after Bxb1 LysB or buffer 
treatment were compared across cell type. If LysB resistance developed, we would expect to see 
cells that had previously survived LysB treatment to be less susceptible to LysB in later 
generations (Figure 8A). Whereas, all cells, regardless of previous treatment, should be 
comparably susceptible to later-generation LysB treatment if no resistance has developed (Figure 
8B). 
After two generations, no evidence of Bxb1 LysB resistance was observed, as all cells 
showed similar survival against LysB treatment (Figure 8C). Our experimental method was 
modified from standard endolysin resistance assay12, but it is possible that we did not run this 
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experiment for enough generations. Repetition alongside a positive control—i.e. an antibiotic 
toward which M. smegmatis is known to develop resistance—is needed. 
 
Figure 8. M. smegmatis did not develop resistance to Bxb1 LysB. 
Models of expected results if cells pretreated with LysB do (A) or do not (B) develop resistance to LysB 
treatment. All M. smegmatis cells showed the same susceptibility to Bxb1 LysB, regardless of pretreatment with 
Bxb1 LysB or protein storage buffer (C). The original (naïve) M. smegmatis cells were passaged and subjected 
to killing assays to control for any effects of extended culturing. 
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3.2.3 Lysterase activity against other mycolata 
While most endolysins have antimicrobial activity only against the natural host bacteria of the 
phages that encode them, little is known about the susceptibility range of lysterases. We 
hypothesized that other mycolic acid-containing bacteria might be susceptible to a protein that 
hydrolyzes mycolic acids from the mycobacterial cell wall. Some species of the genera 
Corynebacterium, Nocardia, and Rhodococcus are known to have mycolic acids in their cell 
walls, but with fewer carbons per chain31. Together with the mycobacteria, these taxa are known 
as the mycolata. Furthermore, unlike in mycobacteria, the biosynthesis of these mycolic acids is 
not essential31. That is, these species can grow in the presence of mycolic acid synthesis 
inhibitors such as isoniazid85,86.  
Killing assays were performed similarly for the mycolata as with the mycobacteria, 
except that the mycolata were incubated with LysB at 30ºC with agitation. With the exception of 
Corynebacterium glutamicum, all members of the mycolata tested were susceptible to both D29 
and Bxb1 LysB proteins (Figure 9). Interestingly, the Bxb1 LysB had an antimicrobial activity 
on C. glutamicum, while the D29 enzyme did not have any effect. The reason for this difference 
in activity is unknown, but an interesting hypothesis is that the N-terminal domain of Bxb1 LysB 
plays a role in its ability to kill C. glutamicum. Therefore, C. glutamicum could provide a model 
system for investigating the differences between the two lysterases. 
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Figure 9. LysB antimicrobial activity against members of the mycolata. 
For the mycolata, killing assays were performed as above for M. smegmatis, except that incubation and growth took 
place at 30ºC. Both D29 and Bxb1 LysB had antimicrobial effect on N. corynebacteroides, R. erythropolis, and C. 
vitaeruminis. Some of these strains saw reduction of survival in as little as one minute of incubation. Only Bxb1 
LysB affected C. glutamicum. No C. glutamicum killing was seen with D29 LysB even if the incubation time was 
extended to 60 minutes (data not shown). 
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3.2.4 Resistance of other Gram-positive and Gram-negative bacteria to lysterases 
We then tested LysB susceptibility on Gram-positive Staphylococcus epidermidis and Bacillus 
cereus and Gram-negative Serratia marcescens and E. coli. Because none of these bacteria 
contain mycolic acids in their cell walls, we hypothesized that they should all be resistant to 
LysB treatment.  Indeed, none of the Gram-positive or Gram-negative bacteria selected were 
susceptible to either LysB (Figure 10).  
 
 
Figure 10. Other Gram-positive and Gram-negative bacteria are not susceptible to LysB treatment. 
Killing assays were performed as above. S. epidermidis and E. coli were incubated and grown at 37ºC, while 30ºC 
was used for S. marcescens and B. cereus. None of the bacteria from outside the Order Actinomycetales were 
affected by treatment with either LysB. In some cases, like S. marcescens, a range of LysB concentrations were used 
to determine if resistance was dose dependent, but the proteins had no effect even at higher concentrations. 
Increasing incubation times to 60 minutes also did not have any effect on survival (data not shown). 
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4.0  LYSTERASE ACTIVITY AGAINST CUTIBACTERIUM ACNES 
We also wished to test the LysB susceptibility of bacteria that 1) do not contain mycolic acids, 
but 2) are closely related to the mycobacteria. Cutibacterium acnes fit this description, as it is a 
member of the Order Actinomycetales, which includes the mycolata, but mycolic acids have 
never been isolated from their cell walls87.  
Originally placed in the genus Corynebacterium88, the acne bacillus was later 
recategorized as a Propionibacterium when it was discovered that it produced propionic acid as a 
major product of glucose fermentation89. Within the last year, a phylogenetic analysis showed 
the genus Propionibacterium to be non-monophyletic, leading to the creation of the novel genus 
Cutibacterium90. Cutibacterium species are differentiated from other former Propionibacterium 
species by their peptidoglycan amino acids (discussed below), their common presence on human 
skin, and their lower G+C content90. C. acnes is the implicated causative pathogen in the skin 
disease acne vulgaris. While acne vulgaris lacks a model organism, C. acnes cannot definitively 
be named the causative pathogen, but the bacterium is present at about 100-fold greater 
concentrations in acne patients than age-matched healthy individuals91. Acne vulgaris is the 
single most common cutaneous disorder, affecting 80% of adolescents and 50% of adults 
worldwide92. Although it is a nonfatal disorder, the United States alone spends approximately 
four billion dollars annually treating acne93. The most common treatments involve topical and/or 
oral antibiotics and retinoids or topical astringents, but many of these have worrying side 
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effects93. Additionally, as antibiotic resistance increases worldwide93, alternative therapeutics—
especially with fewer side effects—are always in demand. 
 
4.1 C. ACNES CELL WALL 
Unfortunately, like the vast majority of bacteria, little is known about the specifics of the C. 
acnes cell wall. The cell-wall sugars of this Gram-positive, aerotolerant anaerobe are glucose, 
mannose, and—in some strains—galactose, with peptidoglycan amino acids alanine, glutamic 
acid, glycine, LL-2,6-diaminopimelic acid (LL-A2PM), and—in some strains—meso-2,6-
diaminopimelic acid (meso-A2PM)87,90. Additionally, part of their historical differentiation from 
other members of the Order Actinomycetales relies on C. acnes lack of mycolic acids88. While C. 
acnes bacteriophages share some genes with the mycobacteriophages, they have low genetic 
diversity, and no lysterase gene has been identified in any C. acnes phage35,94–96. 
4.2 RESULTS 
In the Hatfull laboratory, C. acnes is grown in small, closed anaerobic chambers using 
AnaeroPack sachets or in sealed glass tubes with Oxyrase, an anaerobic media additive. 
Therefore, the killing assays could not be performed entirely anaerobically. Anaerobically grown 
cells were prepared and treated with LysB or buffer in aerobic conditions. Once the timepoints 
were spotted onto A Media plates, the plates were placed in anaerobic chambers to grow. We did 
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not expect nor did we see any evidence that the brief aerobic handling of the cells affected the 
experiment, as C. acnes is aerotolerant. 
Due to their lack of mycolic acids, we predicted that the LysB proteins would have no 
effect on C. acnes 6919. Therefore, we were surprised to find that C. acnes 6919 was susceptible 
to both D29 and Bxb1 LysB (Figure 11). 
4.2.1 Lysterase treatment releases a lipid from C. acnes cells 
To investigate the effect of LysB on C. acnes, we treated whole C. acnes 6919 cells with each 
LysB, performed total lipid extraction, and visualized any changes in lipid profile using TLC 
(Figure 12) as we have previously done for M. smegmatis. Clearly LysB treatment releases at 
least one unidentified lipid from the C. acnes 6919 cell wall (Figure 12, Bxb1 or D29 lanes vs 
buffer lanes). Due to the dearth of information on C. acnes cells wall components, appropriate 
standards could not be run. Instead, we utilized the same running conditions77 as above with M. 
smegmatis (Figure 4), which have been optimized to visualize free mycolic acids (Figure 12A) 
and trehalose dimycolate and trehalose monomycolate (Figure 12B). This way, even though C. 
acnes  lack  mycolic  acids,  any  lipids  with  similar  properties  should  be visible. Scraping the 
Figure 11. LysB antimicrobial activity against C. acnes. 
Both D29 and Bxb1 LysBs had killing activity against C. acnes despite the lack of mycolic acids produced by the 
bacterium. Bxb1 LysB dramatically reduced the number of surviving cfus within five minutes of incubation, while it 
took ten minutes for the D29 enzyme to achieve comparable killing 
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band(s) in question from the silica TLC plate, purifying the lipid(s), and analysis with mass 
spectrometry is a logical next step, but the carbon- and hydrogen-rich nature of lipids 
complicates definitive identification. 
 
 
 
 
 
 
Figure 12. LysB treatment releases at least one lipid from whole C. acnes cells. 
C. acnes cells were treated with either D29 or Bxb1 LysB and analyzed as with M. smegmatis above. Because little 
is known about the C. acnes cell wall, appropriate standards could not be run, but the same running conditions were 
used to enable qualitative comparisons. At least one unidentified lipid (arrows) is released from C. acnes cells 
during LysB treatment as compared to the buffer control when TLC is performed under optimized conditions87 to 
visualize free mycolic acids (A) and the difference between trehalose di- and monomycolate (B). 
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4.2.2 Lysterase activity against C. acnes clinical isolates 
Not only is C. acnes the implicated causative agent in acne vulgaris, it is also an opportunistic 
pathogen, particularly in surgical settings. C. acnes strains involved in different infections have 
been correlated with specific genetic markers97–100. Ribotypes (RT) 1, 4, 5, and 8 are associated 
with acne, RT 3 with eye infections, and RT 6 with blood and medical device infections97. There 
are exceptions to these associations; for example, C. acnes strain KPA 171202 is RT 1, but is 
associated with blood and medical device infections rather than acne100. 
  Because of the variety of C. acnes clinical isolates, we were interested in testing our 
LysBs against a range of C. acnes genetic markers, such as ribotype (Table 1). Killing assays for 
C. acnes clinical isolates were carried out in the same manner as C. acnes 6919. While some of 
our clinical isolates were susceptible to one or both of our LysBs, others were entirely resistant. 
At present, no clear pattern has emerged from the clinical isolate data, and more testing is 
needed.  
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Table 1. LysB effect on C. acnes clinical isolates. 
 
 
 
 
 
C. acnes clinical isolate strains HL036PA1, HL042PA3, and HL110PA4 were susceptible to treatment by either 
LysB protein. Strains HL043PA1, HL013PA1, HL067PA1, and KPA171202 were resistant to both enzymes. C. 
acnes ATCC 6919 is included for comparison. S and R indicate susceptibility or resistance, respectively, to each 
LysB.  
Phylotype, ribotype, and multi-locus sequence type (MLST) are three methods that have been used to 
categorize C. acnes stains. C. acnes strains were originally classified into distinct phylotypes98 based on serological 
agglutination tests and cell wall sugar analysis87. Ribotype refers to the 16s rDNA sequence of each C. acnes strain; 
RT1 is the most abundant, and all other ribotypes have 99% or greater sequence similarity to RT197. MLST relies on 
analyzing seven core housekeeping genes99. 
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5.0  DISCUSSION, CONCLUSIONS, AND FUTURE DIRECTIONS 
Our data clearly show that lysterases from D29 and Bxb1 have antimicrobial activity against 
members of the Order Actinomycetales, and other Gram-positive and Gram-negative species are 
not susceptible to LysB activity. This is in partial agreement with recently published results74,76. 
Both Grover et al and Lai et al saw antimicrobial activity against mycobacteria, but Lai did not 
see activity against any other bacteria they tested. This discrepancy in our results is most likely 
due to sampling, as Lai and colleagues did not test any other members of the Actinomycetales67. 
It could be valuable to continue testing strains within the Order Actinomycetales and less 
closely-related species in the Phylum Actinobacteria to find the limit of LysB susceptibility, 
especially as there are other bacteria within the Actinomycetales that lack mycolic acids such as 
Streptomyces species. Such results could help elucidate the target of LysB activity in C. acnes, 
since LysB’s in vitro ability to hydrolyze ester-linked carbon chains of varying length from p-
nitrophenyl34,35,74 and kill C. acnes, which lacks mycolic acids—the only known biologically 
relevant substrate of LysB activity—suggest that LysB has broader specificity than previously 
anticipated. 
Additionally, it has been previously hypothesized that lysterases could only be useful 
therapeutics when used in combination with endolysins101. While combination therapies many 
increase the range and/or efficacy of LysB therapies, it is clear from our results that—at least in 
the conditions tested—LysBs have antimicrobial activity in the absence of an endolysin. Indeed, 
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in the two instances of endolysin and lysterase combination treatments, LysB-only treatment had 
significantly more antimicrobial activity than endolysin treatment alone, and combined the two 
enzymes did not kill mycobacteria more effectively than the LysB alone21,76. 
 Finally, while more investigation is needed, lysterases appear to be a promising enzyme 
for use in the fight against mycobacterial and C. acnes infections. The ability of LysB to quickly 
degrade the mycobacterial outer membrane and the ease with which the proteins can be 
overexpressed and purified suggest that lysterases could be a potentially useful tool in 
diagnosing Mtb infections, as they could replace harsh chemicals and lengthy sonications during 
DNA extraction. Whether LysBs could be useful as an Mtb therapeutic is still unknown, as the 
question of delivery through granulomas is unanswered. Lai et al.76 found that exogenous 
lysterase treatment of Mtb-infected macrophages resulted in the reduction of the bacteria, but this 
result should be viewed with a healthy dose of skepticism until more research is conducted. Our 
results are more promising for LysB use against C. acnes, as most acne vulgaris treatments are 
applied topically. Furthermore, topical application eliminates the concern of potential antibody 
generation against LysB that comes with intravenous administration. In fact, the University of 
Pittsburgh has filed a patent for the use of lysterases against C. acnes, and Dermalytica Inc. has 
optioned the patent for development. 
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6.0  MATERIALS AND METHODS 
6.1 PLASMIDS 
The original Bxb1 LysB expression plasmid (pDB1) was created by cloning the Bxb1 LysB gene 
PCR product into the pET21a+ vector using NdeI and EcoRI restriction enzyme sites. The 
catalytically inactive mutant Bxb1 LysB expression plasmid (pDB2) was created from pDB1 
using Q5 (New England Biolabs) site-directed mutagenesis (SDM) to change the catalytic serine 
158 to alanine. The N-terminal 77 amino acids of the Bxb1 LysB were deleted from pDB1 using 
Q5 SDM to create pDB3. Gibson assembly was utilized to create the Bxb1 LysB-fluorescent 
protein fusion constructs, pDB4 and pDB5, which have the lysterase fused to Clover and super-
folder GFP (sfGFP), respectively. The DNA templates for the fluorescent proteins were provided 
by Jenna Zalewski from the Andrew Van Demark lab (University of Pittsburgh) in the form of 
separate plasmids containing Clover-hRock and sfGFP-thrombin. Q5 SDM was used delete the 
77 N-terminal amino acids of Bxb1 LysB from pDB4 to create a ΔN-Bxb1-Clover construct, 
pDB6, and all Bxb1 LysB amino acids except for the first 77 to create a ΔC-Bxb1-Clover 
protein: pDB7. Catalytically inactive mutants of pDB4 and pDB6 were constructed in the same 
manner as pDB2 and were named pDB8 (catalytically inactive full-length Bxb1-Clover) and 
pDB9 (catalytically inactive ΔN-Bxb1-Clover), respectively. The D29 LysB expression plasmid 
(pLAM3) was created by Dr. Laura Marinelli during her time as a graduate student in the Hatfull 
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lab. All plasmids used a pET21a+ backbone; therefore, the origin was oriE, the selection marker 
was ampicillin/carbenicillin, and each protein had a C-terminal His-6 tag. A list of these 
plasmids and the primer required for their construction can be found in Tables 2 and 3, 
respectively. 
 
 
 
 
 
 
 
Table 2. Expression plasmids used in these studies. 
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6.2 PROTEIN OVEREXPRESSION AND PURIFICATION 
Protein induction and purification was carried out similarly for all of the constructed proteins. 
BL21 (DE3) E. coli cells (Invitrogen/Life Technologies) carrying the LysB plasmid were grown 
to OD600 0.5 to 0.7 at 37°C in LB containing carbenicillin (50 µg/mL), followed by induction 
with 2 mM IPTG overnight (18 h) at 18°C with shaking. Cells were pelleted and suspended in 
1mL lysis buffer (500 mM NaCl, 250 mM Tris pH 8, 10% glycerol, 1 mM BME) per gram of 
pelleted cells and then frozen at -80°C. Pellets were thawed and sonicated 30x 30s bursts on ice. 
Lysate was separated from the pellet by centrifugation at 13,000 rpm for 30 min at 4°C. The 
lysate was added to 2 mL per original 500 mL culture of nickel-NTA agarose beads (Qiagen) and 
rocked at 4°C for at least 1 hour. The beads were then washed sequentially by pipetting within 
the column at 4°C with 10 mL of lysis buffer (3 times), 15 mL of lysis buffer with 10 mM 
imidazole (3 times), and 15 mL of lysis buffer with 50 mM imidazole (4 times). The beads were 
allowed to settle in the column and bound protein was eluted with 10 mL of 150 mM imidazole 
in lysis buffer. A supplemental elution of 5 mL of lysis buffer with 250 mM imidazole was used 
to remove any additional bound protein. Samples of each elution and supplemental elution 
fraction were analyzed via SDS-PAGE and fractions containing significant amounts of protein 
were concentrated using dialysis against storage buffer (50 mM Tris pH 8, 50 mM NaCl, 50% 
glycerol). Protein was stored at -20°C. Concentrations were determined via Bradford 
colorimetric assay (Bio-Rad). 
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6.3 KILLING ASSAY: COLONY GROWTH AFTER LYSTERASE TREATMENT 
Cells and treatment conditions were prepared in 1.5 mL Eppendorf tubes according to the 
formula: 50 µL x (# of timepoints + 1). Bacterial cells were grown to log-phase and then pelleted 
and suspended in phosphate buffered saline with Tween (PBST) at a concentration of 1x106 
cfu/mL; one tube of cells per treatment condition. For treatment conditions, like 2 µM Bxb1 
LysB, the specified protein was added to additional storage buffer so that the total volume of 
protein and buffer was equal to the largest volume of protein needed. PBST was then added to 
reach the final volume as calculated by the formula above. Cells were then pelleted again and 
suspended in their treatment condition. Mixtures were incubated at 37°C with agitation. At each 
timepoint, 50 µL of each mixture was removed to a 96 well plate and serially diluted by a factor 
of 10. 5 µL of each dilution was then spotted onto an agar plate of appropriate growth media, and 
the cells were allowed to grow under normal growing conditions. All strains tested can be found 
in Table 4. After several days—long enough for each cell type to form single colonies—
surviving colony forming units were counted. These experiments have also been conducted on 
stationary-phase cells, with similar results. 
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6.4 LYSTERASE RESISTANCE 
A new M. smegmatis culture was resurrected and labeled “naïve,” as they had never seen 
previous treatment with LysB or protein storage buffer. These “Generation 0” cells were used in 
an initial killing assay as described above. New liquid cultures were started from Generation 0 
cells that survived one minute of incubation with buffer or Bxb1 LysB and from an aliquot of the 
Generation 0 naïve cells. These “Generation 1” cells were used in a subsequent killing assay, and 
Table 4. Bacterial strains used in these studies. 
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the method was repeated for a final generation. Survival was then compared to assess whether 
susceptibility to LysB changed if cells were previously treated with LysB. This method was 
modified from Loeffler et al.12 who assayed for resistance over as little as three and as many as 
sixteen generations. 
6.5 LYSTERASE EFFECT ON WHOLE CELL LIPIDS 
M. smegmatis or C. acnes cells were grown in the presence of 14C-acetate for three or twenty-
four hours, respectively. Bacterial cells were grown to log-phase and then pelleted and 
suspended in PBST a concentration of 1x109 cfu/mL. Half of the cells were incubated at 100°C 
for 10 minutes. Cells were then mixed with 8 µM of either LysB or an equivalent volume of 
protein storage buffer. Cell mixtures were incubated at 37°C with agitation for 15 minutes. Total 
lipids were extracted and analyzed by thin layer chromatography, as described in Besra 199877. 
Briefly, cell mixtures were transferred to glass tubes and pelleted. The supernatant was 
discarded. The pellet was suspended in chloroform:methanol (2:1), a magnetic stir bar was 
added, and the extractions were incubated overnight at 37°C with stirring. The following day, 
another 2 mL of chloroform:methanol (2:1) were added and evaporated off. Four milliliters of 
chloroform:methanol:water (4:2:1) were added to the lipids and centrifuged to separate the 
aqueous and organic layers. The bottom layer was removed to a new glass tube and the solvents 
were evaporated off. Finally, the lipids were suspended in 200 µL of chloroform:methanol (2:1), 
the radioactivity of the lipids was measured using a scintillation counter, and samples were 
spotted on the TLC silica plate at equal radioactivity. To separate free mycolic acids, the samples 
were analyzed using a running buffer of chloroform:methanol (97:3). A running buffer of 
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chloroform:methanol:ammonium hydroxide (40:10:1) was used to visualize trehalose di- and 
mono-mycolate. Radiographs were captured using a FujiFilm FLA-5100 imager. 
6.6 CELL LABELING AND IMAGING 
Bacterial cells were grown to log-phase and then pelleted and suspended in PBST at a 
concentration of 1x108 cfu/mL in 1.5 mL Eppendorf tubes. Cells were then pelleted and 
suspended in 3 µM of each Clover fusion protein or an equivalent volume of protein storage 
buffer. After 10 minutes of incubation at 37°C with agitation, the cells were pelleted and the 
supernatant containing any unbound Clover fusion proteins was discarded. Cells were washed 
three times with and then suspended in PBST. 7.5 µL of each sample was spotted onto 
microscope slides, coverslips were attached, and the cells were observed on a fluorescent 
microscope. Meanwhile, 50 µL of each sample was moved to a 96-well plate and fluorescence 
was recorded using a FujiFilm FLA-5100 imager. 
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APPENDIX A  CELL LABELING USING LYSB-FLUORESCENT PROTEIN 
FUSIONS 
A.1  INTRODUCTION 
As discussed in Chapter 2, cell wall binding domains from endolysins of Gram-positive phages 
have been used to selectively label their specific phage’s host bacteria14,16,40,43,44. While a 
definitive CBD has not been identified in any lysterase, the N-terminal domain of the Bxb1 
LysB—which is present in 83% of all LysB proteins—has HHpred predicted structural similarity 
to the CBD of the Pseudomonas phage phiKZ. Additionally, it is hypothesized that all LysB 
proteins should bind quite tightly to their substrates, as it would be detrimental for phages to 
release lytic proteins into their environment, potentially lysing new host cells for the progeny 
phages. Investigating whether all or part of a lysterase could bind and label cells, with the help of 
a fluorescent protein, could not only lead to a diagnostic tool, but also potentially elucidate the 
role of the N-terminal domain. 
A.2 RESULTS AND DISCUSSION 
Clover fluorescent protein was fused to 1) full-length Bxb1 LysB, 2) Bxb1 LysB with the N-
terminal domain deleted (ΔN), and 3) only the N-terminal domain of Bxb1 LysB (ΔC). Storage 
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buffer and Clover fused to human Rho Kinase (hRock, provided by Jenna Zalewski of the 
Andrew Van Demark laboratory) were used as negative controls. Whole M. smegmatis cells 
were incubated with 3 µM of each Clover fusion protein or an equivalent volume of protein 
storage buffer. After 10 minutes, the cells were pelleted, and the supernatant—with any unbound 
Clover fusion proteins—was removed. The cells were washed three times with PBS before being 
spotted onto microscope slides or into 96-well plates for fluorescent imaging.  
The full-length Bxb1 LysB-Clover fusion protein was able to stain M. smegmatis, while 
there was somewhat reduced labeling with the ΔN-Bxb1-Clover and ΔC-Bxb1-Clover fusions 
(Figure 13), suggesting that both domains are necessary for efficient LysB binding. This result is 
not without caveats though, as catalytically active versions of the full-length Bxb1- and ΔN-
Bxb1-Clover fusions were used. At the very least, we expect this to affect the level of 
fluorescence detected in the full-length Bxb1-Clover treated sample, because as cells are lysed, 
their cell debris—presumably still with Bxb1 bound—would be removed during the wash steps. 
Catalytically inactive versions of both proteins have been made, but unfortunately there was not 
time to repeat the experiment with these proteins. It would also be worthwhile to repeat this 
experiment with D29-Clover fusions, including a mutant with the N-terminal domain from Bxb1 
LysB attached to the N-terminus of the D29 LysB-Clover fusion protein.  
Furthermore, these experiments could also be repeated using different bacterial species. It 
would be interesting to see if a LysB-Clover fusion can bind to C. acnes or if differential binding 
can be observed between D29 LysB- and Bxb1 LysB-Clover fusion proteins on C. glutamicum. 
E. coli could be used as a negative control, as E. coli is not susceptible to LysB activity and 
should not contain a LysB target for the fusion protein to bind. 
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Figure 13. Clover fusion protein labeling of live M. smegmatis cells. 
Fluorescent microscopy shows that only the full length Bxb1 LysB-Clover fusion protein was retained by the cells 
after several washes. Buffer and hRock-Clover were used as negative controls. Samples were also measured using a 
fluorimeter. Values were normalized to the buffer-treated sample to control for artifacts like autofluorescence.  
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